SAB Biotherapeutics (SABS) Operating Margin (2021 - 2025)
Historic Operating Margin for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to 29287.09%.
- SAB Biotherapeutics' Operating Margin changed N/A to 29287.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 69102.73%, marking a year-over-year increase of 725254000.0%. This contributed to the annual value of 3244.87% for FY2024, which is 15443200.0% down from last year.
- Latest data reveals that SAB Biotherapeutics reported Operating Margin of 29287.09% as of Q3 2025.
- SAB Biotherapeutics' Operating Margin's 5-year high stood at 29287.09% during Q3 2025, with a 5-year trough of 8726.26% in Q4 2024.
- For the 5-year period, SAB Biotherapeutics' Operating Margin averaged around 1654.83%, with its median value being 160.26% (2022).
- Per our database at Business Quant, SAB Biotherapeutics' Operating Margin tumbled by -74703700bps in 2023 and then surged by 190017700bps in 2025.
- Over the past 5 years, SAB Biotherapeutics' Operating Margin (Quarter) stood at 66.41% in 2021, then tumbled by -448bps to 363.74% in 2022, then plummeted by -1601bps to 6187.9% in 2023, then crashed by -41bps to 8726.26% in 2024, then soared by 436bps to 29287.09% in 2025.
- Its last three reported values are 29287.09% in Q3 2025, 15124.81% for Q2 2025, and 15484.95% during Q1 2025.